Discover
LPAA
Launch One Acquisition Corp.
10.87
8 x 10.80
3 x 10.75
bid
ask
+
0.00
0.00%
6 @ 04:00 PM
10.84 -0.03 (0.28%)
| Ytd | 2.64% | |
| 1y | 3.23% |
10.87
day range
10.87
10.47
52 week range
11.67
| Open | Prev Close | 10.87 | Low | 10.87 | High | 10.87 | Mkt Cap | 312.51M | |
| Vol | 6.00 | Avg Vol | 3.17K | EPS | 0.25 | P/E | 43.48 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 10.81 | 200-d Avg | 10.77 | 1yr Est | 0.00 |
LPAA News
benzinga.com
Launch One Acquisition's Shareholders Approve Extension Of Business Combination Deadline To January
https://www.sec.gov/ix?doc=/Archives/edgar/data/0002015502/000121390026077654/ea0297864-8k_launch.ht
defenseworld.net
Gritstone Asset Management LLC Has $665,000 Position in Launch One Acquisition Corp. $LPAA
Gritstone Asset Management LLC reduced its position in shares of Launch One Acquisition Corp. (NASDA
benzinga.com
Minovia Therapeutics Granted Two New U.S. Patents For Its IP Portfolio
Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnolo
benzinga.com
FDA Grants Orphan Drug Designation To Minovia Therapeutic's Lead Investigational Compound, MNV-201 F
Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnolo
benzinga.com
Minovia Therapeutics' MNV-201 Receives FDA Fast Track And Rare Pediatric Disease Designations For Pe
Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnolo
benzinga.com
Minovia Therapeutics To Go Public Via Merger With Launch One Acquisition Corp., Forming Mito US One
Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnolo